Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引:0
|
作者
Armstrong, April W. [1 ]
Soliman, Ahmed M. [2 ]
Gisondi, Paolo [3 ]
Fang, Siran [2 ]
Patel, Manish [2 ]
Strober, Bruce [4 ,5 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Dermatol, 1450 San Pablo St 5400, Los Angeles, CA 90033 USA
[2] AbbVie Inc, N Chicago, IL USA
[3] Univ Verona, Dept Med, Sect Dermatol & Venereol, Verona, Italy
[4] Yale Univ, Dept Dermatol, New Haven, CT USA
[5] Cent Connecticut Dermatol, Cromwell, CT USA
关键词
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab; ADALIMUMAB;
D O I
10.1007/s13555-024-01293-y
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
IntroductionDespite advancements in the treatment of psoriasis (PsO), there are few head-to-head studies assessing comparative effectiveness of the newest therapies approved to treat PsO. Our objective was to assess the comparative clinical effectiveness of risankizumab and deucravacitinib in patients with moderate-to-severe PsO.MethodsThis placebo-anchored matching-adjusted indirect comparison (MAIC) analysis utilized data from UltIMMa-1/2 risankizumab and POETYK PSO-1/2 deucravacitinib trials. Individual patient data from UltiMMA-1/2 were weighted via propensity score to match POETYK PSO-1/2 published summary data. Rate differences between risankizumab and deucravacitinib were assessed for Psoriasis Area and Severity Index (PASI) 75/90/100, the Static Physician Global Assessment (sPGA = 0 or 0/1), and the Dermatology Life Quality Index (DLQI) 0/1.ResultsAt 16 weeks, risankizumab-treated patients demonstrated statistically significantly higher rates of skin clearance and greater improvement in quality of life (QoL) compared to those treated with deucravacitinib. Across all outcomes, risankizumab demonstrated a lower number needed to treat compared to deucravacitinib. Limitations are potential bias due to unobserved/unmeasurable differences and limited generalizability of the results.ConclusionsThis indirect comparison demonstrates that risankizumab has higher rates of skin clearance and greater improvements in QoL than deucravacitinib. This study will help inform healthcare providers in their treatment and management strategy of PsO.
引用
收藏
页码:3071 / 3081
页数:11
相关论文
共 50 条
  • [21] FEASIBILITY OF MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF OMALIZUMAB (OMA) VS. MEPOLIZUMAB (MEPO) IN MODERATE-TO-SEVERE ASTHMA
    Ayyagari, R.
    Alvares, L.
    Mu, F.
    Hacking, V
    Martinez, R.
    Signorovitch, J. E.
    VALUE IN HEALTH, 2016, 19 (07) : A549 - A549
  • [22] MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF TRALOKINUMAB AND DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS BEYOND WEEK 16
    Torres, Tiago
    Sohrt Petersen, Anne
    Mariela Rosso, Aldana
    Moreira Taveira, Christian
    Manuel Carrascosa, Jose
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 48 - 48
  • [23] Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
    Gisondi, Paolo
    Loconsole, Francesco
    Raimondo, Paola
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 120 - 130
  • [24] Efficacy of risankizumab in moderate-to-severe plaque psoriasis by baseline characteristics and prior therapies
    Strober, B.
    Valdecantos, W.
    Zhan, T.
    Lambert, J.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 42 - 43
  • [25] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [26] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Rand, Kim
    Ramos-Goni, Juan Manuel
    Akmaz, Bulent
    Sole-Feu, Laia
    Armario-Hita, Jose-Carlos
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 169 - 182
  • [27] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Kim Rand
    Juan Manuel Ramos-Goñi
    Bülent Akmaz
    Laia Solé-Feu
    José-Carlos Armario-Hita
    Dermatology and Therapy, 2024, 14 : 169 - 182
  • [28] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [29] Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal
    Al-Janabi, A.
    Warren, R. B.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) : 220 - 221
  • [30] Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
    Hannah A. Blair
    Drugs, 2020, 80 : 1235 - 1245